Spruce Biosciences (SPRB) Profit After Tax (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Profit After Tax of -$12.3 million for Q1 2026, up 12.4% year-over-year from -$10.9 million in Q1 2025, and up 16.13% quarter-over-quarter from -$14.7 million in Q4 2025.
Spruce Biosciences (SPRB) Profit After Tax (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Profit After Tax for 8 consecutive years, with -$12.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 12.4% year-over-year to -$12.3 million; the TTM figure through Mar 2026 stood at -$37.2 million (up 32.83% YoY), while the FY2025 annual figure was -$39.0 million, up 26.53% from the prior year.
- Profit After Tax improved to -$12.3 million in Q1 2026 per SPRB's latest filing, from -$14.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$2.1 million in Q2 2025 and bottomed at -$23.6 million in Q4 2024.
- Historically, Profit After Tax has averaged -$11.7 million across 5 years, with a median of -$11.8 million in 2022.
- Annual changes were most pronounced in 2024 — Profit After Tax sank 124.26% — and 2025, when it surged 77.49%.
- Spruce Biosciences' Profit After Tax stood at -$10.5 million in 2022, then decreased by 0.48% to -$10.5 million in 2023, then tumbled by 124.26% to -$23.6 million in 2024, then jumped by 37.75% to -$14.7 million in 2025, then rose by 16.13% to -$12.3 million in 2026.
- Business Quant data shows SPRB's Profit After Tax at -$12.3 million in Q1 2026, -$14.7 million in Q4 2025, and -$8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -16.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.23 Mn |
| Mar 31, 2026 | -12.30 Mn |
| Dec 31, 2025 | -14.67 Mn |
| Sep 30, 2025 | -8.21 Mn |
| Jun 30, 2025 | -2.07 Mn |
| Mar 31, 2025 | -14.04 Mn |
| Dec 31, 2024 | -23.56 Mn |
| Sep 30, 2024 | -8.67 Mn |
| Jun 30, 2024 | -9.18 Mn |
| Mar 31, 2024 | -11.63 Mn |
| Dec 31, 2023 | -10.51 Mn |
| Sep 30, 2023 | -12.35 Mn |
| Jun 30, 2023 | -12.82 Mn |
| Mar 31, 2023 | -12.79 Mn |
| Dec 31, 2022 | -10.46 Mn |
| Sep 30, 2022 | -11.43 Mn |
| Jun 30, 2022 | -11.87 Mn |
| Mar 31, 2022 | -11.76 Mn |
| Dec 31, 2021 | -9.17 Mn |
| Sep 30, 2021 | -11.45 Mn |